NASDAQ:LENZ LENZ Therapeutics (LENZ) Stock Price, News & Analysis $21.86 +1.21 (+5.86%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$20.05▼$22.3150-Day Range$18.38▼$25.1052-Week Range$14.07▼$29.82Volume127,185 shsAverage Volume127,067 shsMarket Capitalization$601.15 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get LENZ Therapeutics alerts: Email Address LENZ Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.17 Rating ScoreUpside/Downside60.1% Upside$35.00 Price TargetShort InterestBearish8.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.81) to ($2.80) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.81 out of 5 starsMedical Sector391st out of 919 stocksBiological Products, Except Diagnostic Industry60th out of 155 stocks 3.6 Analyst's Opinion Consensus RatingLENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about LENZ Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.98% of the float of LENZ Therapeutics has been sold short.Short Interest Ratio / Days to CoverLENZ Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in LENZ Therapeutics has recently decreased by 5.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLENZ Therapeutics does not currently pay a dividend.Dividend GrowthLENZ Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LENZ. Previous Next 2.5 News and Social Media Coverage News SentimentLENZ Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for LENZ Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for LENZ on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LENZ Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for LENZ Therapeutics are expected to grow in the coming year, from ($2.81) to ($2.80) per share.Price to Book Value per Share RatioLENZ Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LENZ Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> About LENZ Therapeutics Stock (NASDAQ:LENZ)LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Read More LENZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LENZ Stock News HeadlinesSeptember 12 at 11:46 AM | finance.yahoo.comLENZ Therapeutics Insiders Up US$178k On US$551.1k InvestmentSeptember 9, 2024 | americanbankingnews.comAnalysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.00September 15, 2024 | Behind the Markets (Ad)Unveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?September 8, 2024 | americanbankingnews.comFinancial Review: LENZ Therapeutics (NASDAQ:LENZ) vs. SOPHiA GENETICS (NASDAQ:SOPH)August 30, 2024 | seekingalpha.comLENZ Therapeutics: Upcoming PDUFA, Strong Data, Some RisksAugust 27, 2024 | globenewswire.comLENZ Therapeutics to Participate in Upcoming Investor ConferencesAugust 26, 2024 | investorplace.comLENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024August 19, 2024 | insidermonkey.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Q2 2024 Earnings Call TranscriptSeptember 15, 2024 | Behind the Markets (Ad)Unveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?August 16, 2024 | seekingalpha.comLENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for LENZ Therapeutics Amidst Strong Market Potential and Positive Product DataAugust 15, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on LENZ Therapeutics (LENZ)August 15, 2024 | markets.businessinsider.comBuy Rating for LENZ Therapeutics on Promising Presbyopia Treatment and Market PotentialAugust 14, 2024 | globenewswire.comLENZ Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | globenewswire.comLENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of PresbyopiaAugust 7, 2024 | globenewswire.comLENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024June 10, 2024 | globenewswire.comLENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024May 30, 2024 | globenewswire.comLENZ Therapeutics to Present at the Jefferies Global Healthcare ConferenceSee More Headlines Receive LENZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/15/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LENZ Previous SymbolNASDAQ:LENZ CUSIPN/A CIK1815776 Webwww.graphitebio.com Phone650-484-0886FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$38.00 Low Stock Price Target$32.00 Potential Upside/Downside+60.1%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.95% Return on Assets-51.59% Debt Debt-to-Equity RatioN/A Current Ratio23.23 Quick Ratio23.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$22.06 per share Price / Book0.99Miscellaneous Outstanding Shares27,500,000Free Float2,248,000Market Cap$601.15 million OptionableN/A Beta0.39 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Evert B. Schimmelpennink (Age 52)President, CEO, Secretary & Director Comp: $886.54kMr. Shawn Olsson (Age 41)Chief Commercial Officer Comp: $532.13kMr. Marc G. Odrich M.D. (Age 65)Chief Medical Officer Comp: $576.95kMr. James W. McCollum (Age 69)Co-Founder & Director Mr. Gerald HornSenior Scientific Advisor & FounderMr. Daniel R. Chevallard CPA (Age 44)Chief Financial Officer Mr. Domenick PorfidiaVice President of SalesMr. David MurphySenior Director of Marketing & Alliance DevelopmentMr. Marvin J. Garrett (Age 73)Senior Vice President of Regulatory & Quality More ExecutivesKey CompetitorsCG OncologyNASDAQ:CGONApogee TherapeuticsNASDAQ:APGEVericelNASDAQ:VCELNovavaxNASDAQ:NVAXBeam TherapeuticsNASDAQ:BEAMView All CompetitorsInsiders & InstitutionsDeerfield Management Company L.P. Series CBought 17,353 shares on 8/15/2024Ownership: 0.476%Marshall Wace LLPBought 22,554 shares on 8/14/2024Ownership: 0.618%Squarepoint Ops LLCBought 10,477 shares on 8/14/2024Ownership: 0.287%Renaissance Technologies LLCBought 13,300 shares on 8/9/2024Ownership: 1.649%Dimensional Fund Advisors LPBought 13,653 shares on 8/9/2024Ownership: 1.019%View All Insider TransactionsView All Institutional Transactions LENZ Stock Analysis - Frequently Asked Questions How have LENZ shares performed this year? LENZ Therapeutics' stock was trading at $16.20 at the beginning of the year. Since then, LENZ shares have increased by 34.9% and is now trading at $21.86. View the best growth stocks for 2024 here. How were LENZ Therapeutics' earnings last quarter? LENZ Therapeutics, Inc. (NASDAQ:LENZ) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.09. Who are LENZ Therapeutics' major shareholders? LENZ Therapeutics' top institutional shareholders include Wealth Enhancement Advisory Services LLC (2.28%), Renaissance Technologies LLC (1.65%), Bank of New York Mellon Corp (1.09%) and Dimensional Fund Advisors LP (1.02%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum. View institutional ownership trends. How do I buy shares of LENZ Therapeutics? Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LENZ) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredTiny Defense Firm Set for Huge Gains with New US ContractOne tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains...Behind the Markets | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.